within Pharmacolibrary.Drugs.ATC.A;

model A16AB14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.19 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.0027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme replacement therapy indicated for the treatment of lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder causing the accumulation of cholesteryl esters and triglycerides. It is approved for use in both pediatric and adult patients with LAL-D.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult and pediatric (≥8 years) patients with LAL-D receiving intravenous sebelipase alfa at a dose of 1 mg/kg; values are geometric mean population PK model parameters from the published study.</p><h4>References</h4><ol><li><p>Shirley, M (2015). Sebelipase alfa: first global approval. <i>Drugs</i> 75(16) 1935–1940. DOI:<a href=&quot;https://doi.org/10.1007/s40265-015-0479-6&quot;>10.1007/s40265-015-0479-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26452566/&quot;>https://pubmed.ncbi.nlm.nih.gov/26452566</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB14;
